Abstract
The study aimed to prepare carbamazepine in solid lipid nanoparticle form (CBZ-SLN) in order to enhance its anticonvulsant effect.
Eight formulations of CBZ-SLNs were prepared by homogenization and ultra-sonication techniques.
The prepared CBZ-SLN showed a high entrapment efficiency% (39.66 ± 2.42%-71.91 ± 1.21%), a small particle size (45.11 ± 6.72-760.7 ± 5.25 nm), and a negative zeta potential (from -21.5 ± 1.02 to -38.4 ± 1.32 mv). The in vitro release study showed the slow release of CBZ from SLNs compared to CBZ aqueous dispersion (
< 0.05). The infrared spectroscopy and the thermal analysis revealed the compatibility of the drug with other ingredients and the presence of drug in the more soluble amorphous estate, respectively. The in vivo study on mice revealed that the CBZ-SLN had a higher anticonvulsant efficacy than CBZ aqueous dispersion after a lethal and chronic dose of pentylenetetrazole (PTZ) (
< 0.05). The histopathological examination of the hippocampus revealed a decrease in the percentage of degeneration in mice treated with the CBZ-SLN compared to the PTZ and CBZ groups.
CBZ can be formulated as SLN with higher anticonvulsant activity than free CBZ aqueous dispersion.